Improved Drug Susceptibility Testing (DST) for Tuberculosis (R01 Clinical Trial Not Allowed)

Funding Opportunity RFA-AI-22-016 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support the development of new diagnostic technologies for tuberculosis (TB) drug susceptibility testing (DST), including point of care (POC) DST and companion diagnostics for new TB drugs.

http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-22-016.html

Source: NIH Funding Opportunities (Notices, PA, RFA) - March 2, 2022 Category: Research Source Type: funding